advertisement

WGC-2021

11.14 Investigational drugs; pharmacological experiments (26)

Showing records 1 to 25

Display all abstracts in classification 11.14 Investigational drugs; pharmacological experiments

Search within classification 11.14 Investigational drugs; pharmacological experiments
94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
Olander KW
Journal of Glaucoma 2021; 30: 473-480
94982 Ripasudil Endgame: Role of Rho-Kinase Inhibitor as a Last-Ditch-Stand Towards Maximally Tolerated Medical Therapy to a Patient of Advanced Glaucoma
Naik M
Clinical Ophthalmology 2021; 15: 2683-2692
94934 Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: the randomized phase II study
Ha A
Acta Ophthalmologica 2021; 0:
94608 Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis
Sakata R
Japanese Journal of Ophthalmology 2021; 65: 591-597
94934 Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: the randomized phase II study
Kim YK
Acta Ophthalmologica 2021; 0:
94982 Ripasudil Endgame: Role of Rho-Kinase Inhibitor as a Last-Ditch-Stand Towards Maximally Tolerated Medical Therapy to a Patient of Advanced Glaucoma
Kapur M
Clinical Ophthalmology 2021; 15: 2683-2692
94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
Sato MA
Journal of Glaucoma 2021; 30: 473-480
94608 Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis
Fujishiro T; Saito H
Japanese Journal of Ophthalmology 2021; 65: 591-597
94934 Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: the randomized phase II study
Jeoung JW
Acta Ophthalmologica 2021; 0:
94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
Abrams MA
Journal of Glaucoma 2021; 30: 473-480
94982 Ripasudil Endgame: Role of Rho-Kinase Inhibitor as a Last-Ditch-Stand Towards Maximally Tolerated Medical Therapy to a Patient of Advanced Glaucoma
Gupta V
Clinical Ophthalmology 2021; 15: 2683-2692
94608 Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis
Nakamura N
Japanese Journal of Ophthalmology 2021; 65: 591-597
94934 Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: the randomized phase II study
Satyal S
Acta Ophthalmologica 2021; 0:
94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
Jerkins GW
Journal of Glaucoma 2021; 30: 473-480
94982 Ripasudil Endgame: Role of Rho-Kinase Inhibitor as a Last-Ditch-Stand Towards Maximally Tolerated Medical Therapy to a Patient of Advanced Glaucoma
Sethi H
Clinical Ophthalmology 2021; 15: 2683-2692
94608 Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis
Honjo M
Japanese Journal of Ophthalmology 2021; 65: 591-597
94934 Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: the randomized phase II study
Kim J
Acta Ophthalmologica 2021; 0:
94982 Ripasudil Endgame: Role of Rho-Kinase Inhibitor as a Last-Ditch-Stand Towards Maximally Tolerated Medical Therapy to a Patient of Advanced Glaucoma
Srivastava K
Clinical Ophthalmology 2021; 15: 2683-2692
94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
Lu F; Dinh P
Journal of Glaucoma 2021; 30: 473-480
94934 Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: the randomized phase II study
Kim S
Acta Ophthalmologica 2021; 0:
94608 Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis
Shirato S
Japanese Journal of Ophthalmology 2021; 65: 591-597
94934 Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: the randomized phase II study
Park KH
Acta Ophthalmologica 2021; 0:
94608 Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis
Miyamoto E
Japanese Journal of Ophthalmology 2021; 65: 591-597
94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
Odani-Kawabata N; Chabi A
Journal of Glaucoma 2021; 30: 473-480
94608 Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis
Yamada Y; Aihara M
Japanese Journal of Ophthalmology 2021; 65: 591-597

Issue 22-2

Change Issue


advertisement

WGC-2021